{"result": "(\"entity\"<|>MECHANICAL VENTILATION<|>EVENT<|>A medical procedure involving the use of machines to assist or replace spontaneous breathing, which was a focus in the trial)\n##\n(\"entity\"<|>BLOOD TRANSFUSION<|>EVENT<|>The process of transferring blood or blood products into one's circulation intravenously, which was less frequent in the hydrocortisone group)\n##\n(\"entity\"<|>RENAL-REPLACEMENT THERAPY<|>EVENT<|>A therapy that replaces the normal blood-filtering function of the kidneys, which was monitored in the trial)\n##\n(\"entity\"<|>NEW-ONSET BACTEREMIA<|>EVENT<|>The presence of bacteria in the blood, which was tracked as an outcome in the trial)\n##\n(\"entity\"<|>NEW-ONSET FUNGEMIA<|>EVENT<|>The presence of fungi in the blood, which was tracked as an outcome in the trial)\n##\n(\"relationship\"<|>HYDROCORTISONE GROUP<|>MECHANICAL VENTILATION<|>Patients in the hydrocortisone group had a shorter duration of the initial episode of mechanical ventilation<|>7)\n##\n(\"relationship\"<|>PLACEBO GROUP<|>MECHANICAL VENTILATION<|>Patients in the placebo group had a longer duration of the initial episode of mechanical ventilation compared to the hydrocortisone group<|>7)\n##\n(\"relationship\"<|>HYDROCORTISONE GROUP<|>BLOOD TRANSFUSION<|>Fewer patients in the hydrocortisone group received a blood transfusion compared to the placebo group<|>6)\n##\n(\"relationship\"<|>PLACEBO GROUP<|>BLOOD TRANSFUSION<|>More patients in the placebo group received a blood transfusion compared to the hydrocortisone group<|>6)\n##\n(\"relationship\"<|>HYDROCORTISONE GROUP<|>RENAL-REPLACEMENT THERAPY<|>The rate of use of renal-replacement therapy was monitored in the hydrocortisone group<|>5)\n##\n(\"relationship\"<|>PLACEBO GROUP<|>RENAL-REPLACEMENT THERAPY<|>The rate of use of renal-replacement therapy was monitored in the placebo group<|>5)\n##\n(\"relationship\"<|>HYDROCORTISONE GROUP<|>NEW-ONSET BACTEREMIA<|>The rate of new-onset bacteremia was tracked in the hydrocortisone group<|>5)\n##\n(\"relationship\"<|>PLACEBO GROUP<|>NEW-ONSET BACTEREMIA<|>The rate of new-onset bacteremia was tracked in the placebo group<|>5)\n##\n(\"relationship\"<|>HYDROCORTISONE GROUP<|>NEW-ONSET FUNGEMIA<|>The rate of new-onset fungemia was tracked in the hydrocortisone group<|>5)\n##\n(\"relationship\"<|>PLACEBO GROUP<|>NEW-ONSET FUNGEMIA<|>The rate of new-onset fungemia was tracked in the placebo group<|>5)\n<|COMPLETE|>", "input": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "parameters": {"model": "gpt-4o", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": [{"role": "user", "content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: the placebo group (median, 10 days [interquartile range, 5 to 30] vs. 12 days [interquartile range, 6 to 42]; hazard ratio, 1.14; 95% CI, 1.06 to 1.23; P<0.001) (Fig. S6C and S6D in the Supplementary Appendix). After adjustment for multiple comparisons, there was no significant between-group difference in the number of days alive and out of the ICU (P=0.047; threshold level for significance after adjustment for multiple comparisons, P=0.005) (Table 2, and Table S11 in the Supplementary Appendix).\nPatients in the hydrocortisone group had a shorter duration of the initial episode of mechanical ventilation than did those in the placebo group (median, 6 days [interquartile range, 3 to 18] vs. 7 days [interquartile range, 3 to 24]; hazard ratio, 1.13; 95% CI, 1.05 to 1.22; P<0.001), but taking into account episodes of recurrence of ventilation, there were no significant differences in the number of days alive and free from mechanical ventilation (Table 2, and Fig. S6G and S6H in the Supplementary Appendix).\nThere were no significant between-group differences with respect to the rate of recurrence of shock, the time to hospital discharge, the number of days alive and out of hospital, the rate of recurrence of mechanical ventilation, the duration and rate of use of renal-replacement therapy, and the rate of development of new-onset bacteremia or fungemia (Table 2, and Fig. S6E and S6F in the Supplementary Appendix).\nFewer patients in the hydrocortisone group than in the placebo group received a blood transfusion (37.0% vs. 41.7%; odds ratio, 0.82; 95% CI, 0.72 to 0.94; P=0.004). Among the patients who received a transfusion, there was no significant between-group difference with respect to the mean total volume of blood transfused (Fig. S7 in the Supplementary Appendix).\nAdverse Events\nA total of 33 adverse events was reported in the trial population, with a higher percentage in the hydrocortisone group than in the placebo group (1.1% vs. 0.3%, P=0.009). There were 6 serious adverse events, with 4 occurring in the hydrocortisone group and 2 in the placebo group (Table 3). The list of protocol violations and the results of the interim analyses are presented in Tables S12 and S13, respectively, in the Supplementary Appendix.\nTable 3\n\nAdverse Events.\nDiscussion\nWe found that the administration of hydrocortisone did not result in lower 90-day mortality than placebo among patients with septic shock. This effect did not differ in any of the six prespecified subgroups. We observed a more rapid resolution of shock and a lower incidence of blood transfusion among patients who received hydrocortisone than among those who received placebo. Patients who had been assigned to receive hydrocortisone had a shorter time to ICU discharge and earlier cessation of the initial episode of mechanical ventilation than did those who had been assigned to receive placebo. There were no significant between-group differences with respect to mortality at 28 days, the rate of recurrence of shock, the number of days alive and out of the ICU or hospital, the duration and rate of recurrence of mechanical ventilation, the rate of use of renal-replacement therapy, or the rate of new-onset bacteremia or fungemia. Patients who had been assigned to receive hydrocortisone had more adverse events than did those who had been assigned to receive placebo, but these events did not affect patient-centered outcomes.\nOur pragmatic trial was designed with statistical power to detect a clinically plausible effect on mortality. To reduce bias, we used a central randomization process and ensured the concealment and blinding of trial-group assignments, which were independently verified. We published our statistical analysis plan before unblinding.\nWe chose 90-day mortality as a patient-centered primary outcome and specifically targeted a population of patients who had high requirements for vital organ support (use of mechanical ventilation and â‰¥4 hours of vasopressor therapy before randomization) and a substantial risk of death. The trial was successful in enrolling the intended population.\nA high proportion of eligible patients received the trial intervention as planned, and few enrolled patients were lost to follow-up. The ratio of patients who underwent randomization to those who were eligible for inclusion was high: 0.69:1, a ratio that approaches that seen in other large-scale trials.29 The inclusion of 69 sites in five countries increases the external validity of the results.\nOur trial differs from previously published trials in several respects.10,11 We administered hydrocortisone by means of continuous infusion, because such a plan has been shown to attenuate the inflammatory response and reverse shock.30 Practice guidelines for septic shock suggest that infusions may minimize potentially harmful metabolic effects of glucocorticoids.15,31 A tapering strategy was not used for the discontinuation of glucocorticoids, because a beneficial effect of these agents on survival was previously reported without tapering.10 A recent study that compared abrupt cessation with a tapering strategy showed no benefits from tapering.32 We did not perform corticotropin testing, because its interpretation in critically ill patients is controversial33-35 and such testing is not recommended in current clinical practice guidelines.15 We excluded patients who had received etomidate before randomization. We did not administer fludrocortisone, because it\n######################\nOutput:"}, {"role": "assistant", "content": "(\"entity\"<|>HYDROCORTISONE GROUP<|>ORGANIZATION<|>The group of patients in the trial who received hydrocortisone treatment)\n##\n(\"entity\"<|>PLACEBO GROUP<|>ORGANIZATION<|>The group of patients in the trial who received a placebo treatment)\n##\n(\"entity\"<|>ICU<|>GEO<|>Intensive Care Unit where patients were treated and monitored)\n##\n(\"entity\"<|>ADVERSE EVENTS<|>EVENT<|>Unintended and harmful events reported during the trial, with a higher percentage in the hydrocortisone group)\n##\n(\"entity\"<|>SEPTIC SHOCK<|>EVENT<|>A severe and potentially fatal condition that was the focus of the trial)\n##\n(\"relationship\"<|>HYDROCORTISONE GROUP<|>PLACEBO GROUP<|>The trial compared the effects of hydrocortisone versus placebo on patients with septic shock<|>8)\n##\n(\"relationship\"<|>HYDROCORTISONE GROUP<|>ADVERSE EVENTS<|>The hydrocortisone group experienced a higher percentage of adverse events compared to the placebo group<|>7)\n##\n(\"relationship\"<|>PLACEBO GROUP<|>ADVERSE EVENTS<|>The placebo group experienced fewer adverse events compared to the hydrocortisone group<|>7)\n##\n(\"relationship\"<|>HYDROCORTISONE GROUP<|>ICU<|>Patients in the hydrocortisone group had a shorter time to ICU discharge<|>6)\n##\n(\"relationship\"<|>PLACEBO GROUP<|>ICU<|>Patients in the placebo group had a longer time to ICU discharge compared to the hydrocortisone group<|>6)\n##\n(\"relationship\"<|>HYDROCORTISONE GROUP<|>SEPTIC SHOCK<|>The hydrocortisone group was part of a trial to assess treatment effects on septic shock<|>9)\n##\n(\"relationship\"<|>PLACEBO GROUP<|>SEPTIC SHOCK<|>The placebo group was part of a trial to assess treatment effects on septic shock<|>9)\n<|COMPLETE|>"}]}